PNEXF
vs
IPH
PNEXF
IPH
Over the past 12 months, PNEXF has underperformed IPH, delivering a return of 0% compared to the IPH's 22% drop.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
PNEXF
IPH
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Pharnext SCA
OTC:PNEXF
|
999 999.9999
USD
|
|||||
|
Innate Pharma SA
PAR:IPH
|
1.518
EUR
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
PNEXF, IPH
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
Pharnext SCA
Revenue
|
|||||||||||
|
Innate Pharma SA
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
PNEXF, IPH
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
Pharnext SCA
OTC:PNEXF
|
|||||||||
|
Innate Pharma SA
PAR:IPH
|
|||||||||
Compare company's free cash flow with its competitors.
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Pharnext SCA | ||||
|
Innate Pharma SA | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
PNEXF, IPH
Performance By Year
PNEXF, IPH
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.